GlassScriptPhysician profile
Ebele C Chira
NPI 1275542664
$3,425.45
in general payments reported to CMS, 2019-2025
24 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $207 · 2021: $639 · 2022: $558 · 2023: $497 · 2024: $370 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350 · Entertainment: $18.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.82 |
| Entertainment | $18.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $516.49 | 2019-2025 | Mounjaro, Zepbound, Lyumjev |
| Novo Nordisk INC | $456.96 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $369.96 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $266.65 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.77 | 2021-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $224.83 | 2021-2025 | Minimed 780g, Minimed 770g |
| Merck Sharp & Dohme LLC | $221.90 | 2019-2021 | |
| Amgen INC. | $203.06 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $202.69 | 2020-2025 | Freestyle Libre 3 |
| Insulet Corporation | $121.25 | 2021-2025 | Omnipod |
| Dexcom, INC. | $103.22 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $91.06 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $75.69 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $74.70 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $55.60 | 2022-2024 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $48.73 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $42.66 | 2019 | |
| Sequel Med Tech, LLC | $20.00 | 2025 | Twiist |
| Optos, INC. | $18.49 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Radius Health, INC. | $17.53 | 2024 | Tymlos |
| Amryt Pharma Holdings LTD | $15.01 | 2022 | |
| Madrigal Pharmaceuticals | $14.16 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $13.92 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebele Chira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.